Impax resolves FDA warning letter; Recipharm to manufacture Parkinson's drug for LobSor;

> Impax Laboratories ($IPXL) reports that it has resolved its FDA warning letter for a plant in Hayward, CA. Release

> Recipharm has reached an agreement to manufacture a proprietary treatment for advanced Parkinson's disease for Sweden-based LobSor Pharmaceuticals. Release

> The EPA has proposed a rule that would make it easier for healthcare providers to dispose of pharmaceutical waste. Blog post

> Kamani Oil Industries announced today that they have become the first Indian vegetable oil industry to get an FDA drug license for manufacture of pharmaceutical-grade oils and fats. Report

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.